Patents by Inventor Anja Von Heydebreck

Anja Von Heydebreck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-1/PD-L1 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20200362040
    Abstract: The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.
    Type: Application
    Filed: August 5, 2020
    Publication date: November 19, 2020
    Inventors: Jean-Marie Cuillerot, Anja von Heydebreck, Guojun Yuan
  • PD-1/PD-L1 inhibitors for the treatment of cancer
    Patent number: 10800846
    Abstract: The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: October 13, 2020
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Jean-Marie Cuillerot, Anja von Heydebreck, Guojun Yuan
  • PD-1/PD-L1 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20180244781
    Abstract: The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.
    Type: Application
    Filed: February 23, 2016
    Publication date: August 30, 2018
    Inventors: Jean-Marie Cuillerot, Anja von Heydebreck, Guojun Yuan
  • BIOMARKERS AND METHODS FOR DETERMINING EFFICACY OF ANTI-EGFR ANTIBODIES IN CANCER THERAPY
    Publication number: 20150197819
    Abstract: The invention relates to biomarkers based on gene expression products and methods for determining the efficacy of anti-EGFR antibodies in the treatment of EGFR expressing cancer. The invention is further related to the prediction of sensitivity or resistance of a patient suffering from EGFR expressing cancer to the treatment of said patient with a specific anti-EGFR antibody. The invention is preferably related to the identification of respective biomarkers that allow a better prediction of the clinical outcome of the treatment with anti-EGFR antibodies in patients with KRAS wild-type tumors. In this context, the invention especially relates to anti-EFGR antibody c225/cetuximab (Erbitux®) and its use in patients suffering from colorectal Cancer (CRC).
    Type: Application
    Filed: March 25, 2015
    Publication date: July 16, 2015
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Christopher STROH, Anja VON HEYDEBRECK
  • BIOMARKERS AND METHODS FOR DETERMINING EFFICACY OF ANTI-EGFR ANTIBODIES IN CANCER THERAPY
    Publication number: 20120094863
    Abstract: The invention relates to biomarkers based on gene expression products and methods for determining the efficacy of anti-EGFR antibodies in the treatment of EGFR expressing cancer. The invention is further related to the prediction of sensitivity or resistance of a patient suffering from EGFR expressing cancer to the treatment of said patient with a specific anti-EGFR antibody. The invention is preferably related to the identification of respective biomarkers that allow a better prediction of the clinical outcome of the treatment with anti-EGFR antibodies in patients with KRAS wild-type tumors. In this context, the invention especially relates to anti-EFGR antibody c225/cetuximab (Erbitux®) and its use in patients suffering from colorectal Cancer (CRC).
    Type: Application
    Filed: June 15, 2010
    Publication date: April 19, 2012
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Christopher Stroh, Anja Von Heydebreck